Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014.
“The third quarter marked another period of consistent growth for EXPAREL across a broad array of surgical procedures,” said Dave Stack, president, chief executive officer and chairman of Pacira. “We believe that this quarter-over-quarter traction continues to underscore the marketplace need for an alternative to opioid-based therapies for managing postsurgical pain.
Help employers find you! Check out all the jobs and post your resume.
